Cancer tracking co Navotek raises $4m

Dan Naveh's Agate fund invested in the firm, ahead of a larger round.

Cancer research start-up Navotek Medical Ltd. has raised $4 million from Agate Medical Investments LP, which was founded by Dan Naveh. Agate made the investment in the form of convertible bonds, ahead of a larger, separate financing round that the company is due to hold in the near future. Navotek previously raised $5 million at the end of 2007 from mid-tech fund Wanaka Capital Partners Mid-Tech Opportunity Fund LP, and US medical device fund Bridge Investment Fund LP, together with Shimon Eckhouse, who also made a pre-seed investment in the company.

Navotek, which was founded in 2005, has developed a technology designed to deliver a greater level of accuracy in radiotherapy treatment of tumors. One of the main problems in treatment of this kind is that, in the attempt to remove growths, healthy tissue is invariably damaged in the process as well. The more focused the radiotherapy is on the growth itself, the greater the likelihood will be of avoiding damage to healthy tissue, and ensuring patients enjoy a reasonable quality of life after they recover.

Agate also recently invested $3 million in Tulip Medical Ltd., which is developing a intragastric implant for curbing appetite and treating obesity.

Published by Globes [online], Israel business news - www.globes-online.com - on September 15, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס